Key Drivers
- Strong gross margin
- Positive FCF/EBITDA
- High leverage & intangibles
AIAI Summary
BAX has shifted from a defensive consumables name to a binary turnaround where near‑term upside depends on demonstrable sequential EBITDA/FCF improvement, credible deleveraging (movement toward ~3x net leverage), and timely Novum remediation—failure on any of these fronts risks impairment-driven downside. Actionable trigger points: two–three consecutive quarters of rising EBITDA and FCF, meaningful net‑debt reduction, and clear Novum commercialization timelines; absent those, consider downside risk materialization.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong gross margin
- •Positive FCF/EBITDA
- •High leverage & intangibles
Baxter generates solid gross margins, positive EBITDA and free cash flow but is weighed down by large net losses, heavy debt and oversized intangibles that raise impairment and solvency risk.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Breached support
- •Fresh low
Over the last month BAX fell roughly 25% from $21.57 to a fresh low of $16.15, breaching short-term support near $17.0–$17.5 and leaving $21.0–$22.5 as key resistance, signaling continued downside risk until those levels are reclaimed.
~25% decline to $16.15 (fresh low on 2026-03-20)
Sentiment & News
Key News Insights:
- •Disappointing guidance
- •CFO transition
- •Turnaround uncertainty
Baxter faces near-term execution and communication risk after disappointing guidance, a delayed Investor Day and a CFO transition, making the stock a high-risk turnaround bet with potential upside only if the turnaround gains traction.
Expect elevated stock volatility and downside risk until management stabilizes execution and provides clearer guidance
Similar Companies in Healthcare
Other companies in the same sector with AI ratings